You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 4, 2024

KARBINAL ER Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Karbinal Er patents expire, and what generic alternatives are available?

Karbinal Er is a drug marketed by Aytu and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-one patent family members in fourteen countries.

The generic ingredient in KARBINAL ER is carbinoxamine maleate. There are seven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the carbinoxamine maleate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Karbinal Er

A generic version of KARBINAL ER was approved as carbinoxamine maleate by GENUS on March 19th, 2003.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for KARBINAL ER?
  • What are the global sales for KARBINAL ER?
  • What is Average Wholesale Price for KARBINAL ER?
Drug patent expirations by year for KARBINAL ER
Drug Prices for KARBINAL ER

See drug prices for KARBINAL ER

Drug Sales Revenue Trends for KARBINAL ER

See drug sales revenues for KARBINAL ER

Pharmacology for KARBINAL ER

US Patents and Regulatory Information for KARBINAL ER

KARBINAL ER is protected by two US patents.

Patents protecting KARBINAL ER

Modified release formulations containing drug-ion exchange resin complexes
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Modified release formulations containing drug--ion exchange resin complexes
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aytu KARBINAL ER carbinoxamine maleate SUSPENSION, EXTENDED RELEASE;ORAL 022556-001 Mar 28, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Aytu KARBINAL ER carbinoxamine maleate SUSPENSION, EXTENDED RELEASE;ORAL 022556-001 Mar 28, 2013 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for KARBINAL ER

See the table below for patents covering KARBINAL ER around the world.

Country Patent Number Title Estimated Expiration
South Korea 101495146 ⤷  Sign Up
Australia 2007227569 Modified release formulations containing drug-ion exchange resin complexes ⤷  Sign Up
South Korea 20080108520 MODIFIED RELEASE FORMULATIONS CONTAINING DRUG - ION EXCHANGE RESIN COMPLEXES ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.